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Blockade of the CD154-CD40 costimulatory pathway
prevents the development of experimental autoimmune
glomerulonephritis.
Background. Experimental autoimmune glomerulonephritis
(EAG) was induced in Wistar-Kyoto (WKY) rats by immu-
nization with rat glomerular basement membrane (GBM) in
adjuvant. This model is characterized by anti-GBM antibody
production, accompanied by focal necrotizing glomeru-
lonephritis with crescent formation. There is also glomerular
infiltration by T cells and macrophages. Our hypothesis was
that blocking the interaction between CD154 (CD40L) on Th
cells and CD40 on antigen-presenting cells should inhibit T-cell
activation, and thus the development of EAG.
Methods. The in vivo effects of a hamster anti-rat monoclonal
antibody to CD154 (AH.F5) were examined in EAG starting at
day −1 prior to immunization, day +7 after immunization, or
day +14 after immunization.
Results. When administered from day−1 at a dose of 10 mg/kg
intraperitoneally three times per week for the duration of the
study (4 weeks), AH.F5 resulted in a marked reduction in cir-
culating anti-a3(IV)NC1 antibodies, deposits of IgG on the
GBM, albuminuria, deposits of fibrin in the glomeruli, severity
of glomerular abnormalities, and numbers of glomerular T cells
and macrophages. When administered from day +7 at the same
dose, AH.F5 resulted in a moderate reduction in the severity of
disease, while administration from day +14 had no significant
effect.
Conclusion. These studies demonstrate for the first time that
early blockade of the CD154-CD40 T-cell costimulatory path-
way can prevent the development of crescentic nephritis, and
that delayed treatment can reduce the severity of disease. This
confirms the importance of T cell mediated immunity in the
pathogenesis of EAG, and suggests that strategies targeting T-
cell costimulation may provide a novel approach in the treat-
ment of human glomerulonephritis.
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Antigen-specific T-cell activation is regulated by a
two-signal pathway. The first signal is provided by
engagement of the T-cell receptor with the anti-
genic peptide-major histocompatability complex (MHC)
molecule on antigen-presenting cells (APC), and is
an antigen-specific response. However, this interaction
alone is insufficient to induce optimal T-cell activation
without secondary costimulatory signals, which are pro-
vided by binding of specific receptors on T cells with
their ligands on APC. Two of the best characterized
costimulatory pathways are (1) the interaction between
CD40 ligand (CD154) on T cells and CD40 on B cells
or other APC; and (2) CD28 on T cells which interacts
with B7.1/B7.2 (CD80/CD86) on APC [1–7]. Recogni-
tion of processed antigen on the surface of the APC by
the T-cell receptor represents the initial antigen-specific
event leading to cognate interactions. This in turn leads
to up-regulation of CD154 expression on T cells and its
interaction with CD40 on APC. Subsequently, signaling
via CD40, in combination with T-cell–derived cytokines,
results in the expression of CD80/CD86 on APC which
can then fully activate T cells via CD28.
Blockade of the CD154-CD40 pathway with a mono-
clonal antibody directed against CD154 has been shown
to inhibit autoimmune responses in vivo in various
murine models of autoimmune disease [8–12]. Anti-
CD154 monoclonal antibody therapy is effective in pre-
venting the development of collagen-induced arthritis in
the DBA/1J mouse [8], experimental autoimmune thy-
roiditis in the SJL/J mouse [9], experimental allergic en-
cephalomyelitis in the BALB/c mouse [10], and in the
prevention and treatment of lupus-like nephritis in the
NZB/NZW mouse [11], and the SNF1 mouse [12, 13].
In addition to preventing the development of disease
in mainly cell-mediated models of autoimmunity, anti-
CD154 therapy also reduced or prevented autoantibody
production, demonstrating that blockade of the CD154-
CD40 costimulatory pathway results in inhibition of
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humoral as well as cell-mediated immunity. More re-
cently, it has been shown that anti-CD154 monoclonal
antibody given during the induction and chronic stages
of experimental autoimmune myasthenia gravis in the
Lewis rat suppressed progression of disease by down-
regulation of Th 1 responses and up-regulation of CTLA4
[14], demonstrating that blocking the CD154-CD40 T-cell
costimulatory pathway can be effective in both the pre-
vention and treatment of autoantibody-mediated disease.
Experimental autoimmune glomerulonephritis
(EAG), an animal model of Goodpasture’s disease [15,
16], can be induced in genetically susceptible strains of
rat by immunization with heterologous or homologous
preparations of glomerular basement membrane (GBM)
in adjuvant [17–21]. In the model used in this study,
Wistar-Kyoto (WKY) rats given a single injection of
collagenase-solubilized rat GBM in complete Freund’s
adjuvant (CFA) develop sustained anti-GBM antibody
synthesis, linear deposition of IgG on the GBM, deposits
of fibrin in the glomeruli, albuminuria, focal necrotizing
glomerulonephritis with crescent formation, and variable
lung hemorrhage [20]. The main target antigen is the
same in EAG as in Goodpasture’s disease [22, 23], the
noncollagenous (NC1) domain of the a3 chain of type IV
collagen (a3(IV)NC1). The role of anti-GBM antibodies
in the pathogenesis of EAG has been demonstrated
in passive transfer experiments in both rats and mice
with EAG. The successful passive transfer of EAG has
been demonstrated in WKY rats using antibody purified
from the urine of nephritic rats [24], and more recently
by antibody eluted from the kidney of WKY rats with
EAG [abstract; Reynolds et al, J Am Soc Nephrol
12:639, 2001]. A model of EAG in SJL/J mice can also
be transferred using anti-a3(IV)NC1 antibodies pooled
from the serum of nephritic mice [25].
There is mounting evidence for the role of T cells in
EAG. Glomerular infiltration with T cells precedes an
influx of macrophages [26]; transfer of T lymphocytes
can prime naive recipients for disease in BN rats [27];
T cells from WKY rats with EAG proliferate in response
to enriched a3(IV)NC1 [28] and can transfer crescen-
tic nephritis to recipients [29]; and glomerular T cells in
EAG show restricted T-cell receptor CDR3 spectrotypes
[abstract; Walters et al, J Am Soc Nephrol 12:644,
2001]. Furthermore, several approaches to anti-T-cell im-
munotherapy can prevent and ameliorate disease [30].
We have previously shown that cyclosporine A [31] and
anti-CD4 monoclonal antibodies [32] are effective in pre-
venting EAG in the BN rat, and more recently have
demonstrated that anti-CD8 monoclonal antibody is ef-
fective in both the prevention and treatment of EAG in
the WKY rat [33]. Antibodies to intercellular adhesion
molecule-1 (ICAM-1) and leukocyte function-associated
molecule-1 (LFA-1), important in leukocyte migration
and activation, are also effective in both the prevention
and treatment of EAG [34]. Oral administration of GBM
antigen induces mucosal tolerance and prevents the de-
velopment of crescentic nephritis in this model [28], and
similar findings have been reported in EAG in the mouse
[25]. Of particular relevance to the present study, we have
recently shown that blockade of the CD28-B7 costimula-
tory pathway, by either the fusion protein CTLA4-Ig or
a mutant form of CTLA4-Ig (Y100F) which only blocks
B7.1, was effective in preventing the development of cres-
centic nephritis in EAG in the WKY rat [35].
In this paper, we address the question of whether block-
ing the interaction between CD154 on T cells and CD40
on B cells or other antigen presenting cells inhibits T-cell
activation, and thus the development of EAG. We exam-
ined the in vivo effects of blocking the CD154-CD40 path-
way with an anti-CD154 monoclonal antibody (AH.F5)
at different time points during the course of EAG. We
demonstrate for the first time that CD154-CD40 block-
ade is effective in both the prevention and treatment of
crescentic nephritis in the rat. This study confirms the im-
portance of T-cell–mediated immunity in the pathogen-
esis of EAG, and suggests that strategies targeting T-cell
costimulation may provide a novel approach in the treat-
ment of human glomerulonephritis.
METHODS
Experimental animals
Male WKY rats, aged 8 to 10 weeks and weighing 120
to 150 g, were purchased from Charles River (Margate,
UK). All animals were housed in standard conditions and
had free access to normal laboratory diet and water. All
experimental procedures were conducted in accordance
with the UK Animals (Scientific Procedures) Act.
Monoclonal antibody
AH.F5, a novel hamster antirat monoclonal antibody
to CD154, which blocks CD40-dependent T-cell costim-
ulation [36], was kindly provided by Biogen, Inc. (Boston
MA, USA).
Preparation of GBM antigen
Collagenase-solubilized GBM was prepared from
Sprague-Dawley rat kidneys, as previously described [19,
20]. Briefly, the kidneys were decapsulated, the medulla
partly removed, and the cortex passed through a series
of sieves in order to isolate the glomeruli. After exami-
nation by light microscopy to check for tubular contam-
ination, the glomeruli were disrupted ultrasonically, and
the resulting material lyophilized and digested with puri-
fied type XI collagenase (Sigma-Aldrich Company Ltd.,
Poole, UK) for 1 hour at 37◦C.
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Induction of EAG
EAG was induced in WKY rats by a single intramus-
cular injection of collagenase-solubilized rat GBM in an
equal volume of CFA, at a dose of 5 mg/kg body weight
[20, 26]. Serial blood samples were taken by tail artery
puncture under light anesthesia with isoflurane, and 24-
hour urine specimens obtained by placing animals in
metabolic cages.
Assessment of EAG
Enzyme-linked immunosorbent assay (ELISA). Cir-
culating anti-GBM antibody concentrations were mea-
sured in sera from animals with EAG by a solid-phase
ELISA, as previously described [20, 23]. Briefly,
collagenase-digested rat GBM (10 lg/mL), or recom-
binant human a3(IV)NC1 (10 lg/mL) was coated on
to microtiter plates (Life Technologies, Paisley, UK) by
overnight incubation at 4◦C, and an optimum dilution
of test or control sera were applied for 1 hour at 37◦C.
Bound anti-GBM antibody was detected by alkaline
phosphatase-conjugated sheep anti-rat IgG (Sigma-
Aldrich Company Ltd.), and developed using the sub-
strate p-nitrophenyl phosphate (NPP) (Sigma-Aldrich
Company Ltd.). The absorbencies for each well were read
at 405 nm using an Anthos Multiskan ELISA plate reader
(Lab Tech International, Uckfield, UK), and the results
initially calculated as mean optical density for each tripli-
cate sample. In order to compare different experimental
groups, results were finally expressed as a percentage of
the binding obtained with a positive reference serum.
Subclass ELISA. Circulating levels of IgG1 and IgG2a
anti-GBM antibodies were measured in sera from ani-
mals with EAG at week 4 after immunization, by an in-
direct ELISA similar to that previously described [28,
35]. Briefly, recombinant human a3(IV)NC1 (10 lg/mL)
was coated on to microtiter plates by overnight in-
cubation at 4◦C, and an optimum dilution of test or
control sera applied, as described above. The isotypes
of circulating anti-GBM antibodies were detected by
mouse monoclonal antibodies specific for rat IgG1
and IgG2a (Serotec Ltd., Oxford, UK), followed by
goat antimouse IgG (Serotec Ltd.). Levels of bound
IgG1 and IgG2a anti-GBM antibodies were detected by
horseradish peroxidase-conjugated rabbit antigoat IgG
(Sigma-Aldrich Company Ltd.) and developed using
the substrate ortho-phenylenediamine dihydrochloride
(OPD) (Sigma-Aldrich Company Ltd.). The absorbances
for each well were read at 492 nm and the results
expressed as mean optical density for each triplicate
sample.
Rocket immunoelectrophoresis. Urinary albumin con-
centrations were measured in 24-hour urine collections
from animals with EAG by rocket immunoelectrophore-
sis (Amersham Pharmacia Biotech, St. Albans, UK) as
previously described [20, 26]. Briefly, urine samples from
experimental animals were subjected to immunoelec-
trophoresis at 60 volts in an electrophoresis tank contain-
ing Barbitone buffer (BDH Laboratory Supplies, Poole,
UK), pH 9.5, for 6 hours, using a 1% agarose gel (BDH
Laboratory Supplies) containing rabbit antisera to rat al-
bumin raised in our laboratory. Results were calculated
using rat serum albumin standards (which were run at the
same time) and expressed in mg per 24 hours.
Creatinine clearance. Creatinine levels in serum and
urine from animals at week 4 were measured by spec-
trometry using standard techniques. Creatinine clearance
was then calculated for each animal and expressed as
mL/min [26].
Direct immunofluorescence. Deposits of IgG and
fibrin within the glomeruli were detected by direct
immunofluorescence, as previously described [20, 26].
Tissue was embedded in 22-oxacalcitriol (OCT II) em-
bedding medium (Miles Inc., Elkhart, IN, USA) on cork
discs, snap-frozen in isopentane (BDH Laboratory Sup-
plies) precooled in liquid nitrogen, and stored at −70◦C.
Cryostat sections were cut at 5 lm and were incubated
with fluorescein isothiocyanate (FITC)-labeled rabbit an-
tirat IgG (Serotec Ltd.), or goat antirat fibrin (Nordic
Immunology, Tilburg, The Netherlands). The degree of
immunostaining, as judged by intensity of fluorescence,
was graded from 0 to 3+ by a blinded observer.
Light microscopy. Kidney tissue was fixed in 10%
neutral buffered formalin, processed, and embedded in
paraffin wax for light microscopy by standard techniques.
Briefly, 3 lm sections were stained with hemotoxylin and
eosin and periodic acid-Schiff. Fifty glomeruli per section
were graded by a blinded observer as normal, abnormal
(small areas of glomerular hypercellularity and/or focal
necrosis), or severe (>50% of the glomerulus affected by
necrosis and/or crescent formation), and expressed as a
percentage of glomeruli examined [20, 26].
Immunohistology. Kidney sections were stained for
T cells and macrophages using a standard avidin-
biotin complex immunoperoxidase staining technique.
Briefly, formalin-fixed, paraffin embedded kidney sec-
tions were stained with monoclonal antibodies W3/13
(T lymphocytes), OX8 (CD8+ lymphocytes), and ED1
(macrophages) (Serotec Ltd.). Numbers of glomerular T
cells and macrophages were detected using a biotinylated
secondary antibody and avidin-biotin complex (Dako
Ltd., Cambridge, UK). The cellular infiltrate was assessed
by a blinded observer by counting the number of posi-
tively stained cells per 50 consecutive glomeruli in cross-
section [26].
Experimental protocol
Results from our pilot studies examining the in vivo
effects of different doses of antirat CD154 monoclonal
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antibody (AH.F5) from day −1 on the development of
EAG showed that administration of AH.F5 at a dose of 10
mg/kg intraperitoneally three times per week for the du-
ration of the study (4 weeks) was the most effective dose.
In subsequent experiments, groups of animals (N = 5 to
8) immunized with rat GBM in CFA were therefore given
AH.F5 at a dose of 10 mg/kg intraperitoneally three times
per week from (1) day –1 prior to immunization; (2) day
+7 after immunization; or (3) day +14 after immuniza-
tion. Positive control groups (GBM/CFA) were given an
isotyped-matched control monoclonal antibody (Ha 4/8)
(Biogen, Inc.), and a negative control group (CFA alone)
was given saline.
Statistical analysis
Differences between data were determined by the
Mann-Whitney U test (two-tailed). Analysis of variance
(ANOVA) was used to confirm differences between mul-
tiple data.
RESULTS
Circulating anti-GBM antibody concentrations
Positive control rats immunized with rat GBM in
CFA, and given either saline or control monoclonal an-
tibody, produced detectable circulating anti-a3(IV)NC1
antibody levels by week 2, which increased further by
week 3 and peaked at week 4. Animals given AH.F5
from day −1 showed a marked reduction in circulat-
ing anti-a3(IV)NC1 antibody concentrations at all time
points, when compared to positive controls. Animals
given AH.F5 from day +7 showed a slight, though not sig-
nificant, reduction in anti-a3(IV)NC1 antibodies, while
those given AH.F5 from day +14 showed no reduc-
tion in antibody levels. Negative control animals given
CFA alone did not develop anti-a3(IV)NC1 antibodies
(Fig. 1). Similar results were obtained using collagenase-
solubilized GBM as the ligand (results not shown).
Circulating anti-GBM antibody isotypes
Positive control rats immunized with rat GBM in CFA
showed high levels of IgG1 and IgG2a anti-a3(IV)NC1
antibodies at week 4 after immunization. Animals given
AH.F5 from day −1 showed a significant reduction in the
levels of both IgG1 and IgG2a anti-a3(IV)NC1 antibod-
ies, when compared to positive controls. Animals given
AH.F5 from day +7 or from day +14 showed a signifi-
cant reduction in the levels of IgG2a antibodies, but no
reduction in the levels of IgG1 antibodies (Fig. 2).
Direct immunofluorescence for IgG
Positive control rats immunized with rat GBM in CFA
showed strong linear deposits of IgG along the GBM at
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Fig. 1. Effect of AH.F5 monoclonal antibody on circulating anti-
a3(IV)NC1 IgG concentrations in groups of Wistar-Kyoto (WKY) rats
(N = 5–8) with experimental autoimmune glomerulonephritis (EAG).
Results shown represent the mean of each group (SD omitted for rea-
son of clarity). Symbols are: () positive control; () AH.F5 (day −1);
() AH.F5 (day +7); () AH.F5 (day +14); and () negative control.
∗P < 0.01 positive control vs. AH.F5 (day −1).
week 4 after immunization. Animals given AH.F5 from
day −1 showed a marked reduction in deposits of IgG on
the GBM, while those given AH.F5 from day +7 showed
a moderate reduction in deposits of IgG on the GBM.
Animals given AH.F5 from day +14 showed no reduc-
tion in antibody binding. Negative control animals given
CFA alone showed no antibody binding. Results are sum-
marized in Table 1 and illustrated in Figure 3.
Albuminuria
Positive control rats immunized with rat GBM in CFA
produced detectable levels of albuminuria by week 2,
which increased further by week 3 and peaked at week
4. Animals given AH.F5 from day −1 showed a marked
reduction in albumin excretion, to nearly undetectable
levels at all time points, while those given AH.F5 from
day +7 showed a moderate but significant reduction in
albuminuria at week 4. Animals given AH.F5 from day
+14 showed no reduction in albuminuria. Negative con-
trol animals given CFA alone did not develop albumin-
uria (Fig. 4).
Creatinine clearance
Positive control rats immunized with rat GBM in CFA
showed a significant reduction in creatinine clearance
at week 4, while those animals given AH.F5 from day
−1 maintained a normal creatinine clearance, similar to
that of negative control animals given CFA alone. Ani-
mals given AH.F5 from day +7 showed a slight, although
not significant, reduction in creatinine clearance, while
those given AH.F5 from day +14 showed a reduction in
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Fig. 2. Effect of AH.F5 monoclonal antibody on circulating levels of
(A) IgG, (B) IgG1, and (C) IgG2a anti-a3(IV)NC1 antibodies in groups
of Wistar-Kyoto (WKY) rats (N = 5–8) with experimental autoimmune
glomerulonephritis (EAG). Results shown represent the mean ± SD of
each group at week 4 after immunization. ∗P < 0.01 positive control vs.
AH.F5 (day −1).
Table 1. Effects of AH.F5 monoclonal antibody administration on
Wistar-Kyoto (WKY) rats with experimental autoimmune
glomerulonephritis (EAG) on deposition of IgG on the glomerular
basement membrane (GBM) and deposition of fibrin in the glomeruli
Degree of
immunostaining
3+ 2+ 1+ -
IgG
Positive (N = 7) 5 2 0 0
Negative (N = 6) 0 0 0 6
AH.F5 (day −1) (N = 8) 0 0 3 5
AH.F5 (day +7) (N = 5) 1 1 1 2
AH.F5 (day +14) (N = 5) 4 1 0 0
Fibrin
Positive (N = 7) 4 3 0 0
Negative (N = 6) 0 0 0 6
AH.F5 (day −1) (N = 8) 0 0 0 8
AH.F5 (day +7) (N = 5) 0 1 1 3
AH.F5 (day +14) (N = 5) 3 2 0 0
Results are expressed as intensity of fluorescence at week 4 in individual
animals.
creatinine clearance similar to that of positive EAG con-
trols (Fig. 5).
Direct immunofluorescence for fibrin
Positive control rats immunized with rat GBM in CFA
showed large deposits of fibrin within the majority of
glomeruli at week 4. Animals given AH.F5 from day −1
had no detectable deposits of fibrin within the glomeruli,
while those given AH.F5 from day +7 showed a marked
reduction. Animals given AH.F5 from day +14 had no
reduction in fibrin deposits. Control animals given CFA
alone showed no binding. Results are summarized in
Table 1 and illustrated in Figure 3.
Light microscopy
Positive control rats immunized with rat GBM in CFA
showed severe focal necrotizing glomerulonephritis with
crescent formation at week 4. Animals given AH.F5 from
day −1 showed no histologic evidence of fibrinoid necro-
sis or crescent formation. Only mild glomerular abnor-
malities were observed in a minority of the glomeruli
examined. Animals given AH.F5 from day +7 showed
a significant reduction in the severity of fibrinoid necro-
sis/crescent formation, while those given AH.F5 from day
+14 had no reduction in severity of nephritis. Control an-
imals given CFA alone showed normal renal histology.
Results are shown in Figure 6 and illustrated in Figure 7.
Immunohistology
Positive control rats immunized with rat GBM in CFA
showed a glomerular infiltrate of T lymphocytes (which
were predominantly CD8+) and macrophages at week
4. Animals given AH.F5 from day −1 showed a marked
reduction in infiltration of both T cells and macrophages,
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Fig. 3. Direct immunofluorescence of kidney tissue at 4 weeks in
Wistar-Kyoto (WKY) rats with experimental autoimmune glomeru-
lonephritis (EAG). (A) Strong linear deposition of IgG along the
glomerular basement membrane (GBM) in a positive control animal.
(B) Marked reduction in the deposition of IgG in an animal given AH.F5
monoclonal antibody from day −1. (C) Large deposits of fibrin within
the glomerulus of a positive control animal. (D) Negative findings for
fibrin in an animal given AH.F5 monoclonal antibody from day −1
(magnification ×300).
while those given AH.F5 from day +7 showed a moder-
ate but significant reduction. Animals given AH.F5 from
day +14 showed no reduction in glomerular leukocytes
(Fig. 8).
DISCUSSION
Despite considerable research into the role of T-cell
costimulatory molecules in the last few years, the role of
the CD154-CD40 costimulatory pathway in the induction
and maintenance of an ongoing autoimmune response is
still only partially understood [1–7]. To address this issue
in autoimmune renal disease, we have examined the ef-
fect of blocking the CD154-CD40 costimulatory pathway
with a monoclonal antibody to rat CD154 at different
time points during the development of EAG. Previous
studies have demonstrated that blocking the CD154-
CD40 costimulatory pathway is effective in inhibiting the
development of various experimental models of autoim-
mune disease, and effects on both humoral and cellular
immunity have been reported [8–14]. To our knowl-
edge, the only successful studies of anti-CD154 mono-
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Fig. 4. Effect of AH.F5 monoclonal antibody on albuminuria in groups
of Wistar-Kyoto (WKY) rats (N = 5–8) with experimental autoimmune
glomerulonephritis (EAG). Results shown represent the mean of each
group (SD omitted for reason of clarity). Symbols are: () positive con-
trol; () AH.F5 (day −1); () AH.F5 (day +7); () AH.F5 (day +14);
and () negative control. ∗P < 0.01 positive control vs. AH.F5 (day +7);
∗∗P < 0.001 positive control vs. AH.F5 (day −1.
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Fig. 5. Effect of AH.F5 monoclonal antibody on creatinine clearance
in groups of Wistar-Kyoto (WKY) rats (N = 5–8) with experimental
autoimmune glomerulonephritis (EAG). Results shown represent the
mean ± SD of each group at week 4 after immunization. ∗P < 0.01
positive control vs. AH.F5 (day −1).
clonal antibody therapy in renal disease were reported
in lupus-like nephritis in the NZB/NZW mouse [11]
and the SNF1 mouse [12, 13]. In these studies, block-
ade of CD154-CD40 prevented the development of sero-
logic changes and histologic abnormalities in the kidney
[11] and prolonged survival [12] in prenephritic lupus-
prone mice, and decreased the incidence of severe nephri-
tis in mice with established disease [13]. However, no
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Fig. 6. Effect of AH.F5 monoclonal antibody on renal histology at 4
weeks in groups of Wistar-Kyoto (WKY) rats (N = 5–8) with exper-
imental autoimmune glomerulonephritis (EAG). Results shown rep-
resent the severity of glomerular abnormalities which were graded as:
normal, abnormal (small areas of glomerular hypercellularity and/or
focal necrosis) or severe (>50% of the glomerulus affected by necrosis
and/or crescent formation). ∗P < 0.01 positive control vs. AH.F5 (day
+7); ∗∗P < 0.001 positive control v AH.F5 (day −1).
CD154-CD40 blockade studies have been reported in ex-
perimental models of crescentic nephritis. Since EAG
in the WKY rat is induced by an antigen-specific au-
toimmune response directed toward the noncollagenous
domain of the a3 chain of type IV collagen, with a contri-
bution to renal disease from both autoantibodies and T
cells, it provides an excellent model in which to analyze
the effect of CD154-CD40 blockade in the development
of crescentic glomerulonephritis.
In the present study of EAG, we found that blockade
of the CD154-CD40 costimulatory pathway with mon-
oclonal antibodies to CD154 from day −1 before im-
munization resulted in a marked reduction in the lev-
els of circulating anti-a3(IV)NC1 antibodies, deposits of
IgG on the GBM, all features of glomerular injury and
numbers of glomerular T cells and macrophages. There
was also a significant reduction in both IgG1 and IgG2a
anti-a3(IV)NC1 antibodies, suggesting that continued
blockade of the CD154-CD40 pathway prior to immu-
nization reduced both Th 1- and Th 2-like responses.
These findings are most likely due to the inhibition
of activation of antigen-specific T cells reactive with
a3(IV)NC1, thus preventing T-cell–dependent autoan-
tibody production and generation of effector T cells. In-
hibition of the interaction of CD154 with CD40 on APC
may in turn inhibit the expression of CD80/CD86 on the
APC and their interaction with CD28 on the T cell. There-
fore, continued blockade of CD154 could have the ef-
fect of inhibiting two of the major T-cell costimulatory
pathways.
In addition, we found that CD154-CD40 blockade was
still effective after the induction of the immune response,
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Fig. 7. Hematoxylin and eosin stain of kidney tissue at 4 weeks in
Wistar-Kyoto (WKY) rats with EAG. (A) Marked segmental necrosis of
the glomerular tuft with crescent formation in a positive control animal.
(B) Normal glomerular architecture in an animal given AH.F5 from day
−1. (C) Mild segmental proliferation in an animal given AH.F5 from
day +7. (D) Severe necrotizing glomerulonephritis with crescent for-
mation in an animal given AH.F5 from day +14 (magnification ×300).
but before overt glomerular injury. When anti-CD154
monoclonal antibody was administered from day +7 af-
ter immunization there was a moderate reduction in the
severity of disease. Although there was no significant re-
duction in the levels of total circulating anti-a3(IV)NC1
IgG, there was a reduction in the levels of IgG2a, but
not IgG1. This suggests that anti-CD154 monoclonal an-
tibody given at a later time point during the immune
response may preferentially down-regulate Th 1-like re-
sponses and thus cell-mediated immune injury. In sup-
port of this observation, it has recently been reported
that intrinsic renal cell expression of CD40 controls the
glomerular infiltration of Th 1 effector cells in murine ex-
perimental anti-GBM glomerulonephritis [37]. Our data
also supports the suggestion that some degree of T-cell
costimulation is still necessary during an ongoing autoim-
mune response [1–7].
However, when anti-CD154 monoclonal antibody was
administered from day +14, after the onset of glomeru-
lar injury, no reduction in the severity of disease was ob-
served, even although there was still a significant reduc-
tion in levels of circulating IgG2a antibodies. This could
be due to that fact that after this time point CD8+ cy-
totoxic effector cells and macrophages are starting to
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Fig. 8. Immunoperoxidase staining of kidney tissue in groups of
Wistar-Kyoto (WKY) rats (N = 5–8) with experimental autoimmune
glomerulonephritis (EAG) showing the effect of AH.F5 monoclonal
antibody on the numbers of cells infiltrating the glomerulus. (A) T
cells. (B) Macrophages. Results shown represent the mean ± SD of
each group at week 4 after immunization. ∗P < 0.01 positive control vs.
AH.F5 (day +7); ∗∗P < 0.001 positive control vs. AH.F5 (day −1).
infiltrate the glomerulus [26, 33], and the classic T-cell
costimulatory molecules are no longer needed. A con-
tributory factor may be that by week 2 after immuniza-
tion the animals are starting to develop proteinuria, and
some monoclonal antibodies may be passing from the
serum through the damaged glomeruli into the urine.
This suggestion is supported by a drop in the serum lev-
els of anti-CD154 monoclonal antibody from week 2 af-
ter immunization, despite continued administration (data
not shown). However, as a result of this observation,
blockade of the CD154-CD40 costimulatory pathway
alone will probably not work in the treatment of human
anti-GBM disease, since they present with relatively late
disease.
CONCLUSION
We have demonstrated for the first time that blockade
of the CD154-CD40 costimulatory pathway with mono-
clonal antibodies to CD154 can prevent the development
of crescentic nephritis in a rat model of Goodpasture’s
disease, and can reduce the severity of disease even when
given after the induction of the autoimmune response.
This study confirms the importance of T-cell–mediated
immunity in the pathogenesis of EAG, and suggests
that strategies targeting T-cell costimulation may provide
a novel approach in the treatment of human glomeru-
lonephritis [38].
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